The role of the sizing balloon in selection of the patent foramen ovale closure device size

Experimental and Clinical Cardiology

Volumn 13, Issue 1, 2008, Pages 42-46

  Alibegovic, J ^a   Bonvini, R F ^a   Sigwart, U ^a   Dorsaz, P A ^a   Camenzind, E ^a   Verin, Vitali ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Closure device; Patent foramen ovale; Sizing balloon

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ARTICLE; BALLOON OCCLUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; ECHOCARDIOGRAPHY; EQUIPMENT DESIGN; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PATENT FORAMEN OVALE; RECURRENCE RISK; STATISTICAL SIGNIFICANCE; STROKE; VALSALVA MANEUVER;

EID: 41149154453     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Kerut EK, Norfleet WT, Plotnick GD, Giles TD. Patent foramen ovale: A review of associated conditions and the impact of physiological size. J Am Coll Cardiol 2001;38:613-23.
2. Schuchlenz HW, Weihs W, Beitzke A, Stein JI, Gamillscheg A, Rehak P. Transesophageal echocardiography for quantifying size of patent foramen ovale in patients with cryptogenic cerebrovascular events. Stroke 2002;33193-6.
3. Lechat P, Mass JL, Lascault G, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988;318:1148-52.
4. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: An autopsy study of 965 normal hearts. Mayo Clin Proc 1984;59:17-20.
5. Windecker S, Wahl A, Chatterjee T, et al. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: Long-term risk of recurrent thromboembolic events. Circulation 2000;101:893-8.
6. Varma C, Benson LN, Wart MR, et al. Clinical outcomes of patent foramen ovale closure for paradoxical emboli without echocardiographic guidance. Catheter Cardiovasc Interv 2004;62:519-25.
7. Billinger K, Ostermayer SH, Carminati M, et al. HELEX septal occluder for transcatheter closure of patent foramen ovale: Multicentre experience. EuroInterv 2006;1:465-71.
8. Schwerzmann M, Windecker S, Wahl A, et al. Percutaneous closure of patent foramen ovate: Impact of device design on safety and efficacy. Heart 2004;90:186-90.
9. Hara H, Virmani R, Ladich E, et al. Patent foramen ovate: Current pathology, pathophysiology, and clinical status. J Am Coll Cardiol 2005;46:1768-76.
10. Ho SY, McCarthy KP, Rigby ML. Morhological features pertinent to interventional closure of patent oval foramen. J Interv Cardiol 2003;16:33-8.
11. Schuchlenz HW, Weihs W, Horner S, Quehenberger F. The association between the diameter of a patent foramen ovate and the risk of embolic cerebrovascular events. Am J Med 2000;109:456-62.
12. Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovate, atrial septal aneurysm, or both. N Engl J Med 2001;345:1740-6.
13. Marshall AC, Lock JE. Structural and compliant anatomy of the patent foramen ovale in patients undergoing transcatheter closure. Am Heart J 2000;140:303-7.
14. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: A meta-analysis of case-control studies. Neurology 2000;55:1172-9.
15. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovate: Patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002;105:2625-31.
16. Mueller XM, Sigwart U, Regli F, Kappenberger L. Atrial septal defect measurement with a guidewire loop. J Interv Cardiol 1990;3:103-8.
17. Meier B. Closure of patent foramen ovate: Technique, pitfalls, complications, and follow up. Heart 2005;91:444-8.
18. Windecker S, Wahl A, Nedeltchev K, et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol 2004;44:750-8.
19. Wahl A, Meier B, Haxel B, et al. Prognosis after percutaneous closure of patent foramen ovate for paradoxical embolism. Neurology 2001;57:1330-2.
20. Braun M, Gliech V, Boscheri A, et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems. Eur Heart J 2004;25:424-30.
21. Hung J, Landzberg MJ, Jenkins KJ, et al. Closure of patent foramen ovale for paradoxical emboli: Intermediate-term risk of recurrent neurological events following transcatheter device placement. J Am Coll Cardiol 2000;35:1311-6.
22. Martín F, Sánchez PL, Doherty E, et al. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation 2002;106:1121-6.
23. Anzai H, Child J, Natterson B, et al. Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices. Am J Cardiol 2004;93:426-31.
24. Chatterjee T, Petzsch M, Ince H, et al. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism. J Interv Cardiol 2005;18:173-9.
25. Sievert H, Horvath K, Zadan E, et al. Patent foramen ovale closure in patients with transient ischemia attack/stroke. J Interv Cardiol 2001;14:261-6.
26. Bruch L, Parsi A, Grad MO, et al. Transcatheter closure of interatrial communications for secondary prevention of paradoxical embolism: Single-center experience. Circulation 2002;105:2845-8.